Indication
Remimazolam is indicated in adults for procedural sedation. Remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.
Loading your page…
Loading your page…
Conscious Sedation
Marketing Authorisation Holder: Paion Pharma GmbH
EMA Authorisation: 26/03/2021
INN: remimazolam
AI Drug & Interaction Analysis
Free account required
Ask Osler about Byfavo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.